Updated and contextualized version of an article originally published on July 5, 2014
The article retains its original focus by presenting it through a scholarly and accessible perspective, supported by verifiable references.
Authors
- Dr. M. Mondini – Biologist
- Roberto Panzironi –Independent researcher
Note editoriali
- First publication: July 5, 2014
- Last update: April 20, 2026
- Version: 2026 narrative revision
Initial note: This article was previously published and has been updated according to scientific and dissemination criteria. The text is for informational purposes only and does not replace the advice of your doctor. If you have personal questions about tests or therapies, please consult a healthcare professional.
In brief
- Observational studies show that, in the elderly population, non-linear relationships between cholesterol and mortality can emerge: in some groups, higher levels are associated with lower all-cause mortality.
- These results do not automatically equate to causation: the literature includes observations, randomized clinical trials, and genetic studies with diverse and complementary results.
- Randomized trials of LDL lowering with statins reduce cardiovascular events; the effect on all-cause mortality varies with age and baseline risk.
- Alternative explanations include "reverse causation" (disease lowering cholesterol) and differences in context (age, comorbidities, geographical region).
- For clinical and preventive choices, an individual assessment of cardiovascular risk and comorbidity is necessary; the isolated cholesterol value must be interpreted within the overall context.
Abstract: what does science say?
Cholesterol has been a biological measure associated with cardiovascular risk for decades. Observations in very elderly populations have shown inverse associations between some indicators of total or LDL cholesterol and all-cause mortality: in these cohorts, higher levels sometimes coincide with lower mortality from non-cardiovascular causes. However, more robust evidence of causality comes from randomized clinical trials and genetic studies, which indicate that sustained reductions in LDL reduce the risk of cardiovascular events. Differences between observational and experimental results may depend on age, comorbidities, observation duration, and the fact that chronic disease can lower cholesterol levels (reverse causation). In summary: observations indicate non-linear and context-dependent patterns; trials and genetic studies support the causal role of LDL in atherosclerosis, while clinical decisions require individual risk assessment.
What it means in practice
For the general public, the key message is that cholesterol values should not be read in isolation. Several observational studies in very elderly people have documented that relatively high concentrations of total or LDL cholesterol may be associated with lower all-cause mortality compared to very low values [1][2]. However, controlled studies and genetic analyses show that sustained LDL lowering reliably reduces the risk of cardiovascular events (heart attacks, strokes) in large populations, especially in high-risk individuals [5][6][7].
This means that: 1) in frail or very elderly people, the relationship between cholesterol and health is complex and may reflect other processes (for example, chronic diseases that lower cholesterol levels); 2) in subjects with high cardiovascular risk, strategies that reduce LDL have shown benefits on clinical events; 3) for individuals, the decision to treat cholesterol or not requires a comprehensive assessment (age, chronic diseases, cardiovascular risk factors) and consultation with a doctor [5][6][7].
Furthermore, recent literature based on large population cohorts often highlights "U" or "J" shaped curves: higher risks at very low and very high LDL levels, with the minimum risk located in an intermediate range that depends on age and geographical context [2][3][4]. These patterns call for caution in interpreting a single laboratory value and emphasize the importance of follow-up and a global clinical perspective.
Who is interested in these results?
Mainly elderly people and the clinicians who care for them. Observations linking relatively high cholesterol with greater survival come primarily from studies conducted on very elderly individuals (e.g., 85 and older) and on populations with specific characteristics. Consequently, the results do not automatically apply to younger people or those with known cardiovascular disease. For patients with established cardiovascular disease or high risk, trial evidence indicates clear benefits of LDL-lowering therapies [5][6].
How to interpret cholesterol results?
A single cholesterol value should be interpreted along with other elements: age, blood pressure, diabetes, smoking, family history, and the presence of chronic diseases. Low cholesterol levels in elderly people can sometimes reflect underlying health conditions (for example, chronic inflammation or advanced disease) rather than being a protective factor. For this reason, doctors sometimes prefer to monitor trends over time and evaluate the overall clinical picture before modifying therapies or making diagnostic decisions [1][3][9].
Key takeaways
- Observations in very elderly populations have shown inverse associations between cholesterol and all-cause mortality in some contexts.
- Randomized trials indicate that sustained LDL reduction reduces cardiovascular events; the effect on all-cause mortality depends on age and baseline risk [5][6].
- Genetic studies (Mendelian randomization) provide support for the causality of LDL in atherosclerosis and coronary risk [7][8].
- An isolated cholesterol value is not sufficient for clinical decisions: assess overall risk and consult a doctor.
- Differences between observational studies and trials highlight the importance of interpreting results with caution and in the clinical context.
Limitations of the evidence
The literature on cholesterol and mortality includes different types of studies with distinct limitations. Observational studies can show associations (e.g., J or U curves), but do not necessarily prove causality: "reverse causation" is a plausible explanation when pre-existing diseases reduce cholesterol and increase observed mortality [1][3][9].
Randomized trials provide causal evidence for the effects of LDL lowering on cardiovascular diseases; large-scale meta-analyses have found consistent reductions in vascular events and, in some cases, cardiovascular mortality, but the impact on all-cause mortality can vary depending on age and initial risk [5][6].
Genetic studies (Mendelian randomization) offer additional elements to evaluate the biological causality between exposure to elevated LDL and coronary heart disease: overall, these studies support the role of atherogenic lipoproteins in the pathogenesis of cardiovascular diseases, strengthening the interpretation of clinical trials [7][8].
In summary: interesting observations exist, especially for the elderly; but limiting their interpretation without considering trials, genetic evidence, and clinical context can lead to misleading conclusions.
Editorial conclusion
The relationship between cholesterol and longevity is not monolithic: it depends on age, the presence of diseases, overall cardiovascular risk, and the duration of exposure to the lipid profile. Observational studies in very elderly people have in some cases indicated that higher levels of total or LDL cholesterol are associated with lower all-cause mortality; however, experimental and genetic evidence consolidates the role of LDL in atherosclerosis and in reducing the risk of cardiovascular events when its level is lowered in a targeted and controlled manner. For the individual patient, decisions about check-ups, lifestyle changes, or medications must be based on an individual clinical assessment and consultation with a doctor. The goal remains to balance benefits and risks taking into account age, comorbidities, and personal preferences.
Editorial note
This version is updated and organized for clarity, transparency, and verifiability of sources. The information reported here summarizes observational studies, clinical trials, and genetic analyses. It does not constitute personalized therapeutic recommendations.
Scientific research
- [1] Weverling-Rijnsburger AWE, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997. https://doi.org/10.1016/S0140-6736(97)04430-9
- [2] Wu W, Xiao Z, Liang X, et al. Low and High-Density Lipoprotein Cholesterol and 10-Year Mortality in Community-Dwelling Older Adults: The Shanghai Aging Study. Front Med (Lausanne). 2022. https://doi.org/10.3389/fmed.2022.783618
- [3] (Chinese Longitudinal Healthy Longevity Survey) Low-density lipoprotein cholesterol inversely associated with 3-year all-cause mortality among Chinese oldest old. Atherosclerosis. 2015. https://doi.org/10.1016/j.atherosclerosis.2015.01.002
- [4] Associations of Low-density Lipoprotein Cholesterol With All-cause and Cause-specific Mortality in Older Adults in China. J Clin Endocrinol Metab. (Study DOI) https://doi.org/10.1210/clinem/dgae116
- [5] Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010. https://doi.org/10.1016/S0140-6736(10)61545-0
- [6] Cholesterol Treatment Trialists' (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012. https://doi.org/10.1016/S0140-6736(12)60367-5
- [7] Ference BA, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019. https://doi.org/10.1001/jama.2019.14120
- [8] (Genetic studies) Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA. 2017. https://doi.org/10.1001/jama.2017.11467
- [9] Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990. https://doi.org/10.1136/bmj.301.6747.309
Note: Verifiable DOIs are listed for editorial transparency. If you would like a full copy of a single publication or detailed bibliographic clarifications, please request them.